Pregnancy Outcomes in Congenital Heart Disease (POACHD)

Overview

About this study

The purpose of this study is to determine if a biomarker assay obtained peripartum (1st-3rd trimester and post-partum) in patients with adult congenital heart disease can predict future risk of cardiovascular adverse events and determine if temporal changes in biomarkers levels throughout the peripartum period can provide a better risk prediction compared to samples taken at a single time-point.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults (18+)
  • Congenital Heart Disease Diagnosis
  • Currently Pregnant

Exclusion Criteria: 

  • Unable to consent

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 07/19/2024. Questions regarding updates should be directed to the study team contact.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Alexander Egbe, M.B.B.S., M.P.H.

Contact us for the latest status

Contact information:

Adult Congenital Research Program

(507) 293-2565

RSTACHDRESPRG@mayo.edu

More information

Publications

Publications are currently not available